Clinical trials: UC (Urothelial Cancer)
UTUC, UC (Urothelial Cancer)
Screening for Urological Malignancies Using a Urine Exfoliated Cell Fluorescence Assay in a Hematuria Population
This is a prospective, single-center diagnostic clinical study designed to evaluate the performance of a urine-based immunofluorescence cytology test for the detection of urological malignancies in patients presenting with…
- Trial name
- NCT07813260
- Where
- China
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Advanced Solid Tumors
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, drug effects, drug levels and preliminary antitumor activity of BMS-986416 when administered alone and in combination with Nivolumab in participants with select…
- Trial name
- NCT04943900
- Testing
- BMS-986416, Nivolumab
- Where
- 19 sites in United States, Argentina and 5 more
- Volunteers
- 67 people
- Sponsor
- Bristol-Myers Squibb
NSCLC (Non-small Cell Lung Carcinoma), UC (Urothelial Cancer)
A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma
This study evaluated the safety and tolerability of epacadostat (INCB024360) administered in combination with atezolizumab (MPDL3280A) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that were…
- Trial name
- NCT02298153
- Testing
- Epacadostat, Atezolizumab
- Where
- 6 sites in United States
- Volunteers
- 29 people
- Sponsor
- Incyte Corporation
Esophageal and/or Cardia Cancer, Melanoma
A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors
This is a multicenter, randomized, double-blind, parallel-controlled phase I clinical study to evaluate the similarity in PK profile, efficacy, safety and immunogenicity of HLX18 and OPDIVO® in patients with resected esophageal…
- Conditions
- Esophageal and/or Cardia Cancer, Melanoma, Urothelial Carcinoma (UC)
- Trial name
- NCT07518043
- Testing
- HLX18, OPDIVO®
- Where
- 7 sites in China
- Volunteers
- 174 people
- Sponsor
- Shanghai Henlius Biotech
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Bladder Cancer, Urothelial Carcinoma (UC)
Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer
This is a prospective, multicenter observational study designed to collect urine and tumor biospecimens and associated clinical data from patients undergoing evaluation, treatment, or surveillance for urothelial carcinoma.
- Conditions
- Bladder Cancer, Urothelial Carcinoma (UC), Hematuria, Upper Tract Urothelial Cancer
- Trial name
- INSITE (NCT07673016)
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 2,500 people
- Sponsor
- Convergent Genomics, Inc.
Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC)
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 18F-T2 in PET/CT imaging in participants with solid tumors.
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC), Colorectal Cancer, Cervical Cancer
- Trial name
- NCT07557225
- Testing
- 18F-T2 PET/CT
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Urothelial Carcinoma
The Cxbladder Monitoring Study
The aim of this trial is to determine the performance characteristics of the Cxbladder test for the detection of recurrent urothelial carcinoma (UC) in patients with a recent history of urinary tract UC, who have been treated…
- Trial name
- NCT02700659
- Testing
- Cxbladder
- Where
- 11 sites in United States
- Volunteers
- 803 people
- Sponsor
- Pacific Edge Limited
Breast Cancer, Gastric Cancer (GC)
PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors
The purpose of this study is to develop and clinically evaluate 89Zr-labeled HER2-targeted antibody fragments in diagnosis and screening of HER2-positive cancer patients.
- Conditions
- Breast Cancer, Gastric Cancer (GC), Urothelial Carcinoma (UC)
- Trial name
- NCT07023848
- Testing
- 89Zr-LNCab104, 89Zr-LNCab103, 18F-FDG
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Affiliated Hospital of Jiangnan University
Urothelial Carcinoma
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
Urothelial carcinoma (UC) is the ninth most common cancer type worldwide. While the treatment of front-line metastatic urothelial carcinoma (mUC) has improved, there remains a high unmet need for effective therapies for…
- Trial name
- LIVIGNO-3 (NCT06632951)
- Testing
- Livmoniplimab, Budigalimab, Docetaxel
- Where
- 37 sites in United States, Canada and 6 more
- Volunteers
- 150 people
- Sponsor
- AbbVie
Urothelial Carcinoma (UC), Solid Tumors
A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors
This study is a single-arm, open-label, multicenter, non-randomized phase IIa/IIb clinical study to evaluate the efficacy and safety of BL-M09D1 for injection in patients with locally advanced or metastatic urothelial carcinoma…
- Trial name
- NCT07837622
- Testing
- BL-M09D1
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Urothelial Carcinoma, Bladder Cancer
Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
This is a pre-surgical study involving subjects with muscle invasive bladder cancer, or urothelial cancer, who are candidates for neoadjuvant therapy.
- Trial name
- NCT02365766
- Testing
- Pembrolizumab, Gemcitabine, Cisplatin
- Where
- 9 sites in United States
- Volunteers
- 83 people
- Sponsor
- Jason R. Brown
Bladder Urothelial Carcinoma, Lymph Node Metastasis
Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC
This is a prospective, multicenter, Phase Ib clinical study designed to evaluate the safety and preliminary efficacy of propranolol combined with tislelizumab plus gemcitabine/cisplatin (GC) as neoadjuvant therapy for patients…
- Trial name
- NCT07353294
- Testing
- propranolol, Tislelizumab, gemcitabine
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Bladder Cancer (BC), Urothelial Carcinoma (UC)
Trop2-Targeted NIR-II Fluorescent Probe for Identifying Bladder Cancer in Ex Vivo Bladder Samples
Up to 30% of non-muscle-invasive bladder cancer (NMIBC) lesions may be missed by standard white-light cystoscopy, resulting in high tumor recurrence rate. This is a single-center, single-arm, phase 2 prospective study.
- Trial name
- NCT07848854
- Testing
- TTP-ICG fluorescent probe
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Yunnan Cancer Hospital
Metastatic Urothelial Cancer
Paclitaxel and TAK-228 in Urothelial Carcinoma
Phase II Multicentre, single arm, open label study of Paclitaxel and TAK-228 in metastatic urothelial carcinoma (UC) and the impact of PI3K-mTOR pathway genomic alterations
- Trial name
- NCT03745911
- Testing
- Paclitaxel and TAK-228
- Where
- 5 sites in Spain
- Volunteers
- 52 people
- Sponsor
- Associació per a la Recerca Oncologica, Spain
Metastatic Cancer, Solid Tumors
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.
- Conditions
- Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer
- Trial name
- NCT02903914
- Testing
- INCB001158, Pembrolizumab
- Where
- 20 sites in United States, Italy and 2 more
- Volunteers
- 260 people
- Sponsor
- Incyte Corporation
Renal Cell Carcinoma (RCC), Urothelial Carcinoma
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
This is a Phase 1b/2, open-label, multicenter study of DSP-7888 Dosing Emulsion in combination with checkpoint inhibitors (nivolumab or pembrolizumab) in adult patients with solid tumors, that consists of 2 parts: dose search…
- Conditions
- Renal Cell Carcinoma (RCC), Urothelial Carcinoma, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT03311334
- Testing
- DSP-7888 Dosing Emulsion, Nivolumab, Pembrolizumab
- Where
- 19 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Sumitomo Pharma America, Inc.
Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma
Non-invasive Urinary Genomics-Based Risk Assessment for Early Urothelial Carcinoma Diagnosis
This is a two-stage, prospective, single-center observational diagnostic accuracy study evaluating noninvasive urine testing for the detection of urothelial carcinoma (UC).
- Conditions
- Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma, UTUC, Bladder Cancer (BC)
- Trial name
- NCT07614594
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Henan Provincial People's Hospital
Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC)
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of [68Ga]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC)…
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Urothelial Carcinoma (UC)
- Trial name
- NCT05706129
- Testing
- [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452
- Where
- 10 sites in Australia, France
- Volunteers
- 270 people
- Sponsor
- Lumara Bio Oncologics GmbH
Renal Cell Carcinoma, Urothelial Carcinoma
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
This is a comparative study using resected/ biopsied tumors samples collected from renal cell carcinoma and urothelial carcinoma patients who underwent surgical removal of lesions, followed by immune checkpoint blockade (ICB)…
- Conditions
- Renal Cell Carcinoma, Urothelial Carcinoma, Bladder Cancer, Ureter Cancer
- Trial name
- NCT03291028
- Testing
- Immune checkpoint inhibitor targeting PD1
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Fox Chase Cancer Center